Fibrillary aggregated a-synuclein represents the neurologic hallmark of Parkinson's disease and is considered to play a causative role in the disease. Although the causes leading to a-synuclein aggregation are not clear, the GM1 ganglioside interaction is recognized to prevent this process. How GM1 exerts these functions is not completely clear, although a primary role of its soluble oligosaccharide (GM1-OS) is emerging. Indeed, we recently identified GM1-OS as the bioactive moiety responsible for GM1 neurotrophic and neuroprotective properties, specifically reverting the parkinsonian phenotype both in in vitro and in vivo models.Here, we report on GM1-OS efficacy against the a-synuclein aggregation and toxicity in vitro. By amyloid seeding aggregation assay and NMR spectroscopy, we demonstrated that GM1-OS was able to prevent both the spontaneous and the prion-like a-synuclein aggregation. Additionally, circular dichroism spectroscopy of recombinant monomeric a-synuclein showed that GM1-OS did not induce any change in a-synuclein secondary structure. Importantly, GM1-OS significantly increased neuronal survival and preserved neurite networks of dopaminergic neurons affected by a-synuclein oligomers, together with a reduction of microglia activation.These data further demonstrate that the ganglioside GM1 acts through its oligosaccharide also in preventing the a-synuclein pathogenic aggregation in Parkinson's disease, opening a perspective window for GM1-OS as drug candidate.
GM1 oligosaccharide efficacy against α-synuclein aggregation and toxicity in vitro / M. Fazzari, E. Di Biase, L. Zaccagnini, A. Henriques, N. Callizot, M.G. Ciampa, L. Mauri, E.V. Carsana, N. Loberto, M. Aureli, L. Mari, M. Civera, F. Vasile, S. Sonnino, T. Bartels, E. Chiricozzi, G. Lunghi. - In: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS. - ISSN 1388-1981. - 1868:9(2023 Sep), pp. 159350.1-159350.9. [10.1016/j.bbalip.2023.159350]
GM1 oligosaccharide efficacy against α-synuclein aggregation and toxicity in vitro
M. FazzariPrimo
;E. Di BiaseSecondo
;M.G. Ciampa;L. Mauri;E.V. Carsana;N. Loberto;M. Aureli;M. Civera;F. Vasile;S. Sonnino
;E. Chiricozzi
Penultimo
;G. LunghiUltimo
2023
Abstract
Fibrillary aggregated a-synuclein represents the neurologic hallmark of Parkinson's disease and is considered to play a causative role in the disease. Although the causes leading to a-synuclein aggregation are not clear, the GM1 ganglioside interaction is recognized to prevent this process. How GM1 exerts these functions is not completely clear, although a primary role of its soluble oligosaccharide (GM1-OS) is emerging. Indeed, we recently identified GM1-OS as the bioactive moiety responsible for GM1 neurotrophic and neuroprotective properties, specifically reverting the parkinsonian phenotype both in in vitro and in vivo models.Here, we report on GM1-OS efficacy against the a-synuclein aggregation and toxicity in vitro. By amyloid seeding aggregation assay and NMR spectroscopy, we demonstrated that GM1-OS was able to prevent both the spontaneous and the prion-like a-synuclein aggregation. Additionally, circular dichroism spectroscopy of recombinant monomeric a-synuclein showed that GM1-OS did not induce any change in a-synuclein secondary structure. Importantly, GM1-OS significantly increased neuronal survival and preserved neurite networks of dopaminergic neurons affected by a-synuclein oligomers, together with a reduction of microglia activation.These data further demonstrate that the ganglioside GM1 acts through its oligosaccharide also in preventing the a-synuclein pathogenic aggregation in Parkinson's disease, opening a perspective window for GM1-OS as drug candidate.File | Dimensione | Formato | |
---|---|---|---|
Fazzari-BBA2023.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
1.39 MB
Formato
Adobe PDF
|
1.39 MB | Adobe PDF | Visualizza/Apri |
1-s2.0-S1388198123000744-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
3.16 MB
Formato
Adobe PDF
|
3.16 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
1-s2.0-S1388198123000744-am.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
1.61 MB
Formato
Adobe PDF
|
1.61 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.